<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00633347</url>
  </required_header>
  <id_info>
    <org_study_id>VLC-CV-1006-02</org_study_id>
    <nct_id>NCT00633347</nct_id>
  </id_info>
  <brief_title>Use of Antagonist Versus Agonist GnRH in Oocyte Recipient Endometrium Preparation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Valenciano de Infertilidad, IVI VALENCIA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Valenciano de Infertilidad, IVI VALENCIA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oocyte donation is a well established procedure in assisted reproduction treatments (ART). It
      is demonstrated that the use of hormonal substitution therapy, for the synchronization of the
      cycles between the recipients and the donors, provides good results, similar to the ones
      obtained with the natural cycle. In the patients - recipients with preserved ovarian
      function, the recipient's natural cycle is annulled, thus preventing the spontaneous
      Luteinizing Hormone surge. Simultaneously and while waiting for the suitable donor, her
      endometrium is prepared. When the donation occurs and fertilization with the husband sperm
      takes place, her cycle is stimulated again in order to synchronize her window of implantation
      with the donor's ovulation.

      Two different medications are commonly used to inhibit spontaneous ovulation: either GnRHa
      agonist or GnRH antagonists. The present study consists of the comparison between the single
      dose GnRH agonist (Decapeptyl 3,75 IM) and the 7 day dosage of GnRH antagonist (Cetrotide
      0,25 mg). The administration of GnRHa is used fundamentally as a long liberation formulation,
      administered in a single intramuscular injection (IM), which is more practical in terms of
      use. Nevertheless, the unnecessary persistence and the potentially unfavorable action of
      GnRHa during the luteal phase and early gestation have questioned its use. The recovery of
      the Hypophysarian function begins only 8 weeks after the single injection of long liberation
      of triptorelina 3.75 mg. The GnRH antagonist (Cetrotide 0,25 mg) makes the hypofisary
      inhibition shorter than with the analogues and can prepare similar endometrium
      characteristics as a natural cycle. The recipients will be assigned randomly to a group of
      treatment or another.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>implantation rate</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">570</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A: Antagonist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Agonist GnRH</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antagonist GnRH Cetrotide</intervention_name>
    <description>Cetrotide 0.25 mg. daily/ 7 days</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Agonist GnRH Acetate Triptoreline</intervention_name>
    <description>Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  infertile females with preserved gonadal function

          -  ages 18 - 43 years old

        Exclusion Criteria:

          -  BMI: &gt; 28

          -  recurrent miscarriages

          -  severe male factor

          -  important miomas

          -  &gt; 44 years old
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IVI Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2008</study_first_submitted>
  <study_first_submitted_qc>March 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2008</study_first_posted>
  <last_update_submitted>February 14, 2013</last_update_submitted>
  <last_update_submitted_qc>February 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Valenciano de Infertilidad, IVI VALENCIA</investigator_affiliation>
    <investigator_full_name>Carmina Vidal, MD</investigator_full_name>
    <investigator_title>Gynaecologist IVI valencia; Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>oocyte donation</keyword>
  <keyword>endometrial preparation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
    <mesh_term>Cetrorelix</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

